176 related articles for article (PubMed ID: 16460857)
1. Non-clinical development of cancer vaccines: regulatory considerations.
Chabicovsky M; Ryle P
Regul Toxicol Pharmacol; 2006 Apr; 44(3):226-37. PubMed ID: 16460857
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.
Bottomley A; Jones D; Claassens L
Eur J Cancer; 2009 Feb; 45(3):347-53. PubMed ID: 19013787
[TBL] [Abstract][Full Text] [Related]
3. Assuring the quality, safety, and efficacy of DNA vaccines.
Robertson JS; Griffiths E
Mol Biotechnol; 2001 Feb; 17(2):143-9. PubMed ID: 11395863
[TBL] [Abstract][Full Text] [Related]
4. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
5. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
Reeve LM
Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
[TBL] [Abstract][Full Text] [Related]
6. Regulatory expectations during product development for tumour vaccines.
Kawakami K; Puri RK
Dev Biol (Basel); 2004; 116():53-9; discussion 69-76. PubMed ID: 15603183
[TBL] [Abstract][Full Text] [Related]
7. Assuring the quality, safety, and efficacy of DNA vaccines.
Robertson JS; Griffiths E
Methods Mol Med; 2006; 127():363-74. PubMed ID: 16988466
[TBL] [Abstract][Full Text] [Related]
8. United States regulatory considerations for intrauterine progestins for hormone replacement therapy.
Rarick L
Contraception; 2007 Jun; 75(6 Suppl):S140-3. PubMed ID: 17531606
[TBL] [Abstract][Full Text] [Related]
9. Food and Drug Administration proposed testing guidelines for reproduction studies. Revision Committee. FDA Guidelines for Developmental Toxicity and Reproduction, Food and Drug Administration.
Collins TF; Sprando RL; Shackelford ME; Hansen DK; Welsh JJ
Regul Toxicol Pharmacol; 1999 Aug; 30(1):29-38. PubMed ID: 10464044
[TBL] [Abstract][Full Text] [Related]
10. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
11. Lessons from preventive infectious disease vaccines.
Chandler DK; Midthun K; Goldenthal KL
Dev Biol (Basel); 2004; 116():61-6; discussion 69-76. PubMed ID: 15603184
[TBL] [Abstract][Full Text] [Related]
12. Animal studies in the development of medical countermeasures.
Roberts R; McCune SK
Clin Pharmacol Ther; 2008 Jun; 83(6):918-20. PubMed ID: 18323860
[TBL] [Abstract][Full Text] [Related]
13. Food and Drug Administration proposed testing guidelines for developmental toxicity studies. Revision Committee. FDA Guidelines for Developmental Toxicity and Reproduction, Food and Drug Administration.
Collins TF; Sprando RL; Shackelford ME; Hansen DK; Welsh JJ
Regul Toxicol Pharmacol; 1999 Aug; 30(1):39-44. PubMed ID: 10464045
[TBL] [Abstract][Full Text] [Related]
14. International Conference on Harmonisation; guidance on Q4B Evaluation and Recommendation of Pharmacopoeial Texts for use in the International Conference on Harmonisation Regions; Annex 4C on Microbiological Examination of Nonsterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use General Chapter; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2009 Apr; 74(66):15992-3. PubMed ID: 19507323
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of juvenile toxicity.
Barrow PC; Barbellion S; Stadler J
Methods Mol Biol; 2011; 691():17-35. PubMed ID: 20972745
[TBL] [Abstract][Full Text] [Related]
16. Vaccine INDs: review of clinical holds.
Miller DL; Ross JJ
Vaccine; 2005 Jan; 23(9):1099-101. PubMed ID: 15629351
[TBL] [Abstract][Full Text] [Related]
17. Cancer vaccines: clinical development challenges and proposed regulatory approaches for patient access to promising treatments.
Stebbing J; Wood C; Atkins M; Bukowski R; Litwin S; Bower M; Parsa A; Levitsky H
Cancer; 2008 Mar; 112(5):955-61. PubMed ID: 18286505
[TBL] [Abstract][Full Text] [Related]
18. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs.
Zolnik BS; Sadrieh N
Adv Drug Deliv Rev; 2009 Jun; 61(6):422-7. PubMed ID: 19389437
[TBL] [Abstract][Full Text] [Related]
19. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
20. Potency assays for therapeutic live whole cell cancer vaccines.
Petricciani J; Egan W; Vicari G; Furesz J; Schild G
Biologicals; 2007 Apr; 35(2):107-13. PubMed ID: 16882459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
